Researchers have uncovered a new way to attack lymphoma by targeting a non-catalytic region of a key regulatory enzyme, rather than its traditional active site. Researchers at VCU Massey Comprehensive ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

A new UNC study finds that a chemical derived from ashwagandha disrupts viral and cancer processes that make B-cell lymphomas ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

Hodgkin’s lymphoma is definitively diagnosed by the presence of Reed-Sternberg cells, whereas Non-Hodgkin’s lymphoma involves a wider range of lymphoid variations and is classified based on cell ...

MB-105, a CD5-targeted CAR-T cell therapy, has received FDA regenerative medicine advanced therapy designation for relapsed/refractory CD5-positive T-cell lymphoma. The designation aims to expedite ...

The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...

A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved for treating irregular heartbeat to selectively target specific functions of ...